This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
North Chicago, IL-based AbbVie has become one of the top-most pharma companies after it acquired Botox maker Allergan in a cash-and-stock deal for $63 billion in May 2020. The deal is expected to transform AbbVie’s portfolio and lower its dependence on Humira, its flagship product, which has already lost patent protection in Europe and is due to face biosimilar competition in the United States in 2023. AbbVie has one of the most popular cancer drugs in its portfolio, Imbruvica and its newest drugs Skyrizi (risankizumab) and Rinvoq (upadacitinib) position it well for long-term growth.
Sigilon (SGTX) Skyrockets 441% on Buyout Offer From Eli Lilly
by Zacks Equity Research
Eli Lilly (LLY) is set to acquire Sigilon (SGTX) for $14.92 per share, in cash, along with a contingent value right of $111.64 per share.
3 Dividend Kings Yielding Royal Sums
by Ethan Feller
Dividend Kings are stocks that have raised their dividends for at least 50 consecutive years
The Zacks Analyst Blog Highlights Novo Nordisk, Home Depot, Disney, AbbVie and Automatic Data Processing
by Zacks Equity Research
Novo Nordisk, Home Depot, Disney, AbbVie and Automatic Data Processing are included in this Analyst Blog.
Top Stock Reports for Novo Nordisk, Home Depot & Walt Disney
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Novo Nordisk A/S (NVO), The Home Depot, Inc. (HD) and The Walt Disney Company (DIS).
Is Global X SuperDividend U.S. ETF (DIV) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for DIV
AbbVie (ABBV) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
AbbVie (ABBV) closed the most recent trading day at $134.95, moving -0.71% from the previous trading session.
AbbVie (ABBV) Gets CHMP Positive Opinion for Atogepant Approval
by Zacks Equity Research
AbbVie (ABBV) receives a positive recommendation from the European Union's medicinal products committee for the approval of its migraine treatment candidate, atogepant.
Should SPDR Portfolio S&P 500 High Dividend ETF (SPYD) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for SPYD
Investors Heavily Search AbbVie Inc. (ABBV): Here is What You Need to Know
by Zacks Equity Research
AbbVie (ABBV) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
The Zacks Analyst Blog Highlights PepsiCo, AbbVie, Honeywell, Salesforce and Goldman Sachs
by Zacks Equity Research
PepsiCo, AbbVie, Honeywell, Salesforce and Goldman Sachs are included in this Analyst Blog.
AbbVie (ABBV) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
In the latest trading session, AbbVie (ABBV) closed at $137.82, marking a -0.59% move from the previous day.
Top Analyst Reports for PepsiCo, AbbVie & Honeywell
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including PepsiCo, Inc. (PEP), AbbVie Inc. (ABBV) and Honeywell International Inc. (HON).
Lilly's (LLY) Migraine Drug Fails Vis-a-Vis Pfizer's Nurtec ODT
by Zacks Equity Research
Results from a post-approval study show that treatment with Lilly's (LLY) Emgality failed to achieve statistical superiority over Pfizer's Nurtec ODT in preventing episodic migraine in adults.
AbbVie's (ABBV) Skyrizi Meets Ulcerative Colitis Study Goals
by Zacks Equity Research
AbbVie's (ABBV) Skyrizi achieves statistical significance with its primary endpoint of clinical remission in a late-stage study as a maintenance treatment for ulcerative colitis.
Mustang (MBIO) Up 9% on Rare Blood Cancer Study's Upbeat Data
by Zacks Equity Research
Updated data from a clinical study shows that treatment with Mustang Bio's (MBIO) CAR T cell therapy has achieved an overall response rate of 83% in patients with Waldenstrom macroglobulinemia.
Ironwood (IRWD), AbbVie Get FDA Nod for Linzess Label Expansion
by Zacks Equity Research
Ironwood (IRWD) lead drug Linzess gets FDA approval for pediatric functional constipation The label expansion of the drug is expected to boost the company's sales.
Is SPDR Portfolio S&P 500 High Dividend ETF (SPYD) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for SPYD
AbbVie (ABBV) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
AbbVie (ABBV) closed the most recent trading day at $137.73, moving -0.33% from the previous trading session.
Here is What to Know Beyond Why AbbVie Inc. (ABBV) is a Trending Stock
by Zacks Equity Research
AbbVie (ABBV) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Is ProShares S&P 500 Dividend Aristocrats ETF (NOBL) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for NOBL
Vertex (VRTX) Stock Poised Well for Growth in 2023: Here's Why
by Zacks Equity Research
Vertex Pharmaceuticals (VRTX) stock is likely to be driven by several catalysts this year. Multiple clinical milestones are likely to be achieved in 2023 and 2024, both in its CF and non-CF portfolio.
AstraZeneca (AZN) Discontinues Brazikumab Development
by Zacks Equity Research
AstraZeneca (AZN) announces its decision to discontinue the development of brazikumab for all indications under its inflammatory bowel disease program.
Should You Invest in the Fidelity MSCI Health Care Index ETF (FHLC)?
by Zacks Equity Research
Sector ETF report for FHLC
Should Invesco Dynamic Large Cap Value ETF (PWV) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for PWV
AbbVie Inc. (ABBV) is Attracting Investor Attention: Here is What You Should Know
by Zacks Equity Research
AbbVie (ABBV) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.